Cognition Therapeutics shares are trading lower after the company reported data from its Phase 2 SHINE trial of CT1812 in Alzheimer's. CT1812 did not achieve statistical significance on the first of the ordered secondary efficacy endpoints.
Portfolio Pulse from Benzinga Newsdesk
Cognition Therapeutics shares are trading lower after the company reported data from its Phase 2 SHINE trial of CT1812 in Alzheimer's. CT1812 did not achieve statistical significance on the first of the ordered secondary efficacy endpoints.
July 29, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cognition Therapeutics shares are trading lower after the company reported that its Phase 2 SHINE trial of CT1812 in Alzheimer's did not achieve statistical significance on the first of the ordered secondary efficacy endpoints.
The failure to achieve statistical significance on a key endpoint in a clinical trial is a significant setback for a biotech company, likely leading to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100